Ocugen (OCGN) said Thursday the Data and Safety Monitoring Board approved the continuation of its phase 1/2 trial for OCU410, a gene therapy for geographic atrophy secondary to dry age-related macular degeneration.
Initial phase 2 data showed OCU410 is safe and well-tolerated, with no serious adverse events reported, the company said.
Ocugen said dosing will conclude in early 2025, Ocugen said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。